Adding regional hyperthermia to neoadjuvant chemotherapy significantly improves survival in patients with localized high-risk soft tissue sarcoma, researchers report.

Presented by Bernd Kasper University Medical Centre Mannheim, Mannheim, Germany. Gain and test your knowledge in this interactive case study, looking at best practice management of patients with Soft tissue sarcoma (STS), and gain knowledge on emerging combination therapy options for advanced STS. This case study is intended for medical oncologists, surgical oncologists, radiation oncologists and any other clinicians with a strong interest and/or expertise in the treatment of patients with soft-tissue sarcoma (STS). This programme was made possible thanks to independent educational sponsorship from Eli Lilly and Company. Produced by Springer Healthcare IME

The doxorubicin conjugate aldoxorubicin could be a suitable alternative to standard therapies for patients with relapsed or refractory soft tissue sarcoma, say researchers.

This webcast provides the latest information on the current and emerging treatment formats which could improve outcomes for patients with STS, the standards of care for patients with STS and how these are best met within the context of a multidisciplinary team .  ​​​​​​​​​​​​​​ Made possible thanks to an educational sponsorship from Eli Lilly and Company.

Breast cancer was the most common diagnosis, accounting for 30.3% of all cases, followed by soft-tissue sarcomas (20.0%), brain cancer (10.0%), osteosarcoma (6.6%), and hematologic cancers (5.3%).

The cohort of 803 English patients aged 12–24 years at time of diagnosis included 155 patients with germ cell and trophoblastic neoplasms, 77% of whom had testicular cancer, as well as patients with leukemia, lymphoma, carcinoma, central nervous system or bone tumors and soft tissue sarcoma.

David Hong, from The University of Texas MD Anderson Cancer Center in Houston, USA, and team collated data from three clinical trials of adult, adolescent, and pediatric patients undergoing treatment for a broad range of tumors including soft tissue sarcoma, and cancers of the thyroid, salivary gland, lung, colon, and breast.

Here we report on the optimal radiotherapy regimen for patients with small-cell lung cancer, as well as the outcomes of adding evofosfamide to doxorubicin in the first-line soft tissue sarcoma setting and continuing nivolumab after progression in advanced melanoma.

In this roundup we report on three phase III trials, two investigating trastuzumab emtansine in HER2-positive breast cancer and one assessing tailored neoadjuvant therapy in soft tissue sarcoma, and also on an analysis of postmarketing safety events.

He is also involved in clinical and biological research in the field of soft tissue sarcomas.

By Lynda Williams medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group See also: Steady decline in serious comorbidities among pediatric cancer survivors Regional hyperthermia justified in localized high-risk soft tissue sarcoma